Solventum Co. (NYSE:SOLV) Given Consensus Recommendation of "Hold" by Brokerages

Solventum Co. (NYSE:SOLV - Get Free Report) has been assigned a consensus recommendation of "Hold" from the eleven ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $78.86.

A number of equities research analysts have issued reports on SOLV shares. The Goldman Sachs Group increased their price objective on shares of Solventum from $63.00 to $71.00 and gave the stock a "sell" rating in a research note on Monday. Mizuho increased their price objective on shares of Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a research note on Monday. Wells Fargo & Company raised their price target on shares of Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a research note on Friday. Morgan Stanley raised their price target on shares of Solventum from $60.00 to $73.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. Finally, Piper Sandler raised their price target on shares of Solventum from $75.00 to $84.00 and gave the company a "neutral" rating in a research note on Friday.

Institutional Investors Weigh In On Solventum

Hedge funds have recently added to or reduced their stakes in the business. Modus Advisors LLC acquired a new stake in Solventum during the 4th quarter worth approximately $25,000. Clarity Asset Management Inc. acquired a new stake in Solventum during the 4th quarter worth approximately $25,000. Stonebridge Financial Group LLC acquired a new stake in Solventum during the 4th quarter worth approximately $26,000. Raiffeisen Bank International AG acquired a new stake in Solventum during the 4th quarter worth approximately $29,000. Finally, Crews Bank & Trust bought a new position in Solventum during the 4th quarter worth approximately $32,000.

Solventum Price Performance

Solventum stock traded down $1.21 during trading hours on Friday, reaching $78.95. 1,156,834 shares of the stock were exchanged, compared to its average volume of 1,448,847. The company has a market cap of $13.64 billion and a P/E ratio of 28.71. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum has a twelve month low of $47.16 and a twelve month high of $85.92. The stock has a 50 day moving average of $73.02 and a two-hundred day moving average of $70.33.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.